Scale Advanced Therapy Delivery to Expand Global Patient Access

Date
Tuesday, December 08, 2026Tue, Dec 8, 2026
Time
1pm EST / 12pm CST / 11am MST / 10am PST / 6pm GMT1pm EST
Duration
60 min— Live + Q&A
  • Earn a Certificate of Live Attendance
  • AI Webinar Explorer available after event

About this webinar

As advanced therapy medicinal products (ATMPs) move closer to mainstream adoption, expanding patient access across regions presents growing regulatory, operational and healthcare system challenges. Successfully scaling cell and gene therapy delivery requires coordinated strategies that address regional barriers while supporting healthcare system readiness and global expansion.

This webinar brings together expert perspectives from across the advanced therapies ecosystem to explore how developers and stakeholders can overcome barriers to global patient access. The discussion will examine opportunities to navigate regulatory complexity, harmonize operational strategies and establish scalable approaches to advanced therapy delivery.

Drawing on insights from the Advanced Therapy Treatment Center (ATTC) Network and real-world examples, the discussion will explore how healthcare system readiness, patient access initiatives and cross-sector collaboration can support advanced therapy delivery in the UK and beyond. Attendees will also gain insights into operational challenges, supply chain considerations and strategic partnerships that can facilitate global expansion.

Register for this webinar to learn how coordinated regulatory, operational and healthcare system strategies can help expand patient access to advanced therapies across global markets.

Who should attend

This webinar will appeal to professionals involved in advanced therapy development, commercialization, healthcare delivery and patient access, including:
  • Cell and Gene Therapy Development professionals
  • Market Access and Commercialization professionals
  • Regulatory Affairs professionals
  • Supply Chain and Logistics professionals
  • Clinical Operations professionals
  • Healthcare System and Treatment Center leaders
  • Strategic Partnerships and Business Development professionals

What you will learn

Attendees will gain insights into:
  • Scaling patient access beyond regional boundaries
  • Regulatory complexity and opportunities for greater global harmonization
  • Healthcare system readiness and lessons for building scalable supply chains for advanced therapies
  • Real-world insights from navigating critical operational challenges
  • The role of strategic partnerships in supporting commercial growth and global expansion

Featured Speakers

Emily Merrell, Director of ATTC Network Coordination, CGT Catapult

Emily Merrell

Director of ATTC Network Coordination · CGT Catapult

Emily Merrell has worked within the Healthcare sector for over 25 years with global development experience spanning biotech, pharma, CROs and the National Healthcare System (NHS). Her clinical development experience spans all therapeutic areas and stages of the clinical development lifecycle, from First-in-Human trials to Long-Term Follow-Up and Medical Affairs. Before joining the Cell and Gene Therapy Catapult as the current Director of the ATTC network Coordination, she was Senior Director of Therapeutic Expertise and Head of the Centre for Cell & Gene Therapy at ICON, driving the strategic & operational growth of the Centre’s capabilities, which supported the delivery of over 170 cell and gene therapy clinical trials over the last five years across a diverse range of therapeutic areas, development phases and technologies.

In addition to drug development, Emily has worked as a project consultant within the NHS, where she led the development and implementation of a virtual COVID hospital that resulted in improved outcomes for COVID-19 patients. Emily has a passion for enabling new ways of working by challenging ‘traditional models’ and cultivating more integrative, systems-based working, driving improvements in health outcomes for patients worldwide. She is also Co-Chair for ATMP Engage and sits on the Board of Directors for Genetic Alliance-UK.

Laurie Baylor Curtis, Vice President, Clinical Operations Quell Therapeutics Ltd.

Laurie Baylor Curtis

Vice President · Clinical Operations Quell Therapeutics Ltd.

Laurie Baylor Curtis is the Vice President of Clinical Operations at Quell Therapeutics. With over two decades of experience in clinical operations and biotech-driven clinical development, Laurie has held senior leadership roles across renowned organizations in the life sciences sector. She’s an active member of multiple strategic and industry advisory boards, including the Bioindustry Association’s Subject Matter Expert roundtable, Advanced Therapeutic Treatment Centres Industry Advisory Group and the UK Clinical Research Facility Network.

Her prior roles include Vice President and Head of Global Development Operations at Sangamo Therapeutics, as well as leading clinical operations at Nordic Nanovector ASA and GlaxoSmithKline. Her expertise spans strategic oversight, clinical trial management and operational leadership for emerging markets and global development initiatives across several therapeutic areas, with expertise in delivering complex clinical programmes.

Alison Pritchard, Vice President, Business Development, EMEA, Cryoport Systems

Alison Pritchard

Vice President, Business Development, EMEA · Cryoport Systems

Alison Pritchard is Vice President of Business Development, EMEA, at Cryoport Systems. With extensive experience in the life sciences sector, she works with biotechnology and pharmaceutical organizations, supporting the development and delivery of advanced therapies, with a particular focus on cell and gene therapy.

Partner for this event

Cryoport Systems

Cryoport Systems is a market leader in globally integrated temperature-controlled supply chain support for critical, irreplaceable products and materials in the Life Sciences industry. We are already trusted to support nearly 800 active cell and gene therapy clinical trials and over 20 leading commercial products worldwide, delivering unparalleled, integrated supply chain services for products, therapies and treatments requiring unique, specialized temperature-controlled management. And, as the Life Sciences constantly evolve and advance, so do we.

Live: Tue Dec 8